Abstract: Glucagon-like peptide-1 (GLP-1)-based therapies, GLP-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is) are widely used for the treatment of type 2 diabetes. Increasing evidence suggests that they may provide neuroprotection. The aim of this MiniReview was to systematically evaluate the proposed mechanism of action for GLP-1-based therapies in ischaemic brain damage in animals. We performed a literature search using MEDLINE, EMBASE and The Cochrane Library. GLP-1-based therapies administered before, during or after experimental stroke in diabetic and non-diabetic animals were evaluated. We reviewed 27 studies comprised of 20 involving GLP-1RAs and seven involving DPP-4Is. Both GLP-1RAs and DPP-4Is affected the acute inflammatory response secondary to ischaemia by reducing inflammation, endothelial leakage and excitotoxicity. Both treatments also reduced oxidative stress and apoptosis. GLP-1RAs significantly reduced infarct volume when administered acutely, but not later after stroke. The reported effects of DPP-4Is on infarct volume were inconsistent. GLP-1-RAs reliably improved functional outcome, but the effects on cerebral blood flow were inconclusive. These neuroprotective effects were often attributed to activation of the GLP-1 receptor, but non-GLP-1R-mediated effects have also been suggested. Both GLP-1RAs and DPP-4Is significantly affected inflammation, oxidative stress and apoptosis in animal stroke models; however, data from clinical trials only report therapeutic efficacy for GLP-1RAs. Thus, GLP-1RA administration is the most promising treatment to pursue for patients at risk of stroke or immediately after stroke. Future studies should address acute and prophylactic treatments in stroke patients with and without diabetes.
Stroke is a major cause of death and disability worldwide [1] . One prominent type of stroke, ischaemic, is currently treated by removing the obstructing blood clot. This is done using thrombolysis or thrombectomy during the hyperacute phase. These treatments have a limited therapeutic time window of 4.5-6 hr after stroke, so few patients are eligible [2] . Currently applied secondary prophylactic treatments also do not fully prevent recurrent strokes. Thus, there is a need for new treatments for patients with ischaemic stroke.
Glucagon-like peptide-1 (GLP-1)-based therapies, including GLP-1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4Is), are widely used to treat type 2 diabetes. GLP-1RAs activate the GLP-1 receptor (GLP-1R) in a glucose-dependent manner. Specifically, GLP-1R activation reduces plasma glucose levels by increasing insulin secretion and reducing glucagon secretion from the pancreas. Alternatively, DPP-4Is inhibit the breakdown of endogenously produced GLP-1 and other molecules such as gastric inhibitory polypeptide (GIP). They can also modulate intracellular pathways independent of the enzymatic action of DPP-4 [3] .
Evidence from animal studies suggests that GLP-1-based therapies may be used as cardio-or neuroprotectants. In clinical trials of patients with type 2 diabetes, some GLP-1RAs [4, 5] , but not DPP-4Is [6] [7] [8] , reduce the risk of cardiovascular disease by primary prevention. The GLP-1RA lixisenatide was, however, not reported to significantly improve the rate of major cardiovascular events compared to placebo, when administered to diabetic patients with recent acute coronary syndrome [9] . Similar studies have not been performed in high-risk patients without diabetes, so it is unknown whether such a difference between compounds also applies to non-diabetic patients and in acute stroke.
The mechanisms of action for GLP-1-based therapies in stroke have been thoroughly investigated in animal studies, but similar analysis using clinical trials in stroke patients has begun only recently (ClinicalTrials.gov NCT02829502). Furthermore, GLP-1-based therapies may be used to treat other neurological disorders other than strokes such as Parkinson's disease and Alzheimer's disease [10] .
How GLP-1 might decrease risk of cerebrovascular disease or improve memory is not fully understood. GLP-1 may modulate various pathophysiological mechanisms by affecting brain glucose levels [11] , the blood-brain barrier (BBB) [12] or the central regulation of heart rate and blood pressure. Different GLP-1RAs might have variable effects based on different compound structures, modes of administration and pharmacokinetics. Liraglutide, a long-acting GLP-1RA, can pass the BBB to penetrate the circumventricular organs and hypothalamic neurons [13] . However, it is unclear whether other GLP-1RAs can pass an intact or disrupted BBB. Interestingly, DPP-4Is likely do not cross an intact BBB [14] . Thus, GLP-1RAs and DPP-4Is have different pharmacological properties, resulting in different effects on the ischaemic brain that may underlie the varied prevention of cardiovascular disease reported by clinical trials.
In this systematic MiniReview, we have summarized the currently available animal studies of ischaemic brain damage treated with either GLP-1RAs or DPP-4Is. We evaluated their proposed mechanisms of action in ischaemic stroke and suggested possible differences in these mechanisms between DPP-4Is and GLP-1RAs. We examined this specifically in relation to the failure of DPP-4Is to improve cardiovascular outcome in patients with diabetes.
Methods
Search strategy. MEDLINE, EMBASE and The Cochrane Library were searched using free-text terms and medical subject heading (MeSH). A uniform search strategy was applied to these databases to identify pre-clinical interventional in vivo animal studies that investigated the effects of GLP-1-based therapies in experimental ischaemic stroke. The primary MeSH terms and keywords used were as follows: glucagon-like peptide 1, GLP-1 receptor agonist, dipeptidyl peptidase 4 inhibitor, gliptins, cerebrovascular disorders, experimental stroke and neuroprotection (search string is given in Data S1). No date range filters were used in the search to maximize capture of all relevant literature. The last search was performed on the 30 August 2016. Articles were cross-referenced to identify others of interest. Studies were screened by title, abstract and full text. Two authors (IM and J € O) independently performed an abstract review and those that met the inclusion criteria received a full-text screen. Any disagreement on the relevance of the retrieved studies was settled by a third author (CK). The review was reported in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (2009).
Inclusion and exclusion criteria. Inclusion criteria were studies that used: (i) animals with and without diabetes; (ii) treatment with GLP-1, GLP-1RAs or DPP-4Is before, during or after stroke; (iii) experimental ischaemic stroke of all durations; and (iv) A control group. Exclusion criteria were studies that included (i) induced traumatic brain injury, cerebral haemorrhage or haemorrhagic transformation; (ii) exclusive investigation of Alzheimer's disease, Parkinson's disease, sensory neuropathy or cardiovascular effects; (iii) analysis only of in vitro effects; (iv) text in other languages than English; (v) no full text; and (vi) human studies.
Data extraction. Information extracted from each study included the (i) characteristics of the GLP-1-based therapy used (dose, administration route and timing of administration), (ii) animal characteristics (species, sex, age and comorbidity), (iii) type of ischaemia model and occlusion technique, (iv) characteristics of the control group, (v) methodology, and (vi) outcome measures. Outcome measures were noted under the following categories: GLP-1R expression, downstream pathways, inflammation, endothelial leakage, excitotoxicity, oxidative stress, cerebral oedema, apoptosis, neuronal damage, neuronal regeneration, infarct volume, functional outcome and cerebral blood flow (CBF). No effort was made to pool quantitative data from different studies due to variations in methodology. Summary measures were differences in means between treatment groups. The level of significance was set to p < 0.05.
Quality assessment. The guidelines 'Animal Research: Reporting In Vivo Experiments' (ARRIVE) were used to assess the quality of research for the included experimental animal studies [15] .
Results

Study selection.
The literature search yielded 497 results of which 420 studies were non-duplicates, 387 studies were excluded after review of title and abstract, and 33 studies were identified for further detailed evaluation ( fig. 1 ). After evaluation, six additional studies were excluded based on the exclusion criteria.
Characteristics of included studies.
A total of 27 papers were included. Twenty studies applied GLP1RAs and seven applied DPP-4Is. Characteristics of the included GLP-1-based therapies are summarized in table 1, and key characteristics of included studies are summarized in table 2.
The timing of drug administration varied between studies. Eight studies administered GLP-1RAs pre-ischaemia [16] [17] [18] [19] [20] [21] [22] [23] , eight post-ischaemia [24] [25] [26] [27] [28] [29] [30] [31] and four both pre-and postischaemia [32] [33] [34] [35] . For the seven studies involving DPP-4Is, one study applied the drugs pre-ischaemia [36] , one postischaemia [37] and five studies both pre-and post-ischaemia [38] [39] [40] [41] [42] . The drugs were primarily administered intraperitoneally, but some used subcutaneous, intravenous, intracerebral or intragastric delivery methods.
Mouse (C57BL/6), rat (Sprague Dawley/Wistar/Wistar albino) and gerbil (Mongolian) animal models were used (n = 1766). Fifteen studies tested non-diabetic animals [16, 20-23, 25, 28, 29, 31, 33-35, 37, 38, 42] , six used diabetic/hyperglycaemic animals [19, 26, 27, 30, 32, 36] , and six studies included both non-diabetic and diabetic [17, 18, 24, [39] [40] [41] . Diabetes was induced by streptozotocin [17-19, 30, 36] , highfat diet [24, 39, 40] or genetically modified animal strains including db/db mice [27, 41] , Goto-Kakizaki rats [32] and hyperglycaemia induced by infusion of 50% dextrose [26] .
In 21 of the studies, the middle cerebral artery was occluded; in five, the common carotid artery was occluded bilaterally [18, [34] [35] [36] 41] ; and in one study, a three-vessel occlusion technique was used [42] . The vast majority of stroke models were performed using the intraluminal filament insertion method, although some studies used occlusion clips [18, 34-36, 41, 42] , electrocoagulation [31] or endothelin-1 administration [37] .
All studies but one [21] used a non-active vehicle as a control, and some studies also investigated sham-operated animals [16, 18, 19, 21, 30, 31, [33] [34] [35] [36] 41] , other kinds of GLP-1-based therapies [18, 25, 27, 37, 38] , other administration routes [23] or other drug classes [16, 19, 30, 33, 40] . Five studies observed the effects of GLP-1R suppression using knockout animals [20, 38] or specific short hairpin ribonucleic acid (RNA) sequences to target the GLP-1R [21] [22] [23] .
Primary outcome in this MiniReview was molecular mechanisms involved in stroke-related neuroprotection and changes in infarct volumes. Immunohistochemistry and gene and protein expression analyses (Western blot analysis, enzyme-linked immunosorbent assay [ELISA] , reverse transcription polymerase chain reaction, RNA analysis and cDNA analysis) were the predominant techniques used to evaluate the presence and action of the involved molecules. Analyses were performed in cortical, striatal and hippocampal tissues. Infarct volumes were visualized by staining with triphenyl tetrazolium chloride or cresyl violet.
Secondary outcome was changes in functional outcome and CBF. Functional outcome was quantified using tests for neurological deficits, motor behaviour or cognitive ability. CBF was evaluated using a laser Doppler device or infrared thermal imaging. Plasma insulin was measured by ELISA and blood glucose by a glucometer.
GLP-1 receptor expression and downstream pathways.
Following induction of ischaemic stroke, expression of the GLP-1R was up-regulated in astrocytes, GABAergic interneurons and microglia [33, 35] . GLP-1R expression increased in the ischaemic area 1 day after induction of cerebral ischaemia but declined the following days. A secondary period of increased expression was observed after 10 days in astrocytes and interneurons [35] , and neuroprotective effects were reported in conjunction with GLP-1R expression. Furthermore, Teramoto et al. [29] reported GLP-1R expression on the cerebral endothelium. Administration of GLP-1RAs in experimental stroke stimulated the molecules phosphoinositide 3-kinase (PI3K), cyclic adenosine monophosphate (cAMP), protein kinase B (Akt), protein kinase A (PKA) and cAMP response element-binding protein (CREB) [21, 23, 29, 31] , which were all inhibited by GLP-1R suppression [21, 23] .
Inflammation, endothelial leakage and excitotoxicity. Most studies examined the effects of GLP-1-based therapies on the inflammatory response after stroke ( fig. 2 ). Two drugs, [18] (continued) exenatide [26] and sitagliptin [36] , both reduced production of the pro-inflammatory cytokine, tumour necrosis factor alpha (TNF-a). Sitagliptin also reduced interleukin-6 (IL-6) expression and enhanced production of the anti-inflammatory cytokine, interleukin-10 (IL-10) [36] . Darsalia et al. [24] reported that exenatide did not affect monocyte chemoattractant protein-1 (MCP-1), interleukin-1b (IL-1b) and TNF-a expression when administered from 1.5 hr to 3 days post-ischaemia, although a trend towards MCP-1 reduction was observed. Furthermore, exenatide significantly attenuated expression of hypoxia-inducible factor 1 alpha (HIF-1-a) [34] , which stimulates expression of inflammatory cytokines [43] . Activity and expression of the inducible nitric oxide synthase (iNOS) were significantly reduced by rhGLP-1 [30] , exenatide [29] , and a dual-GLP-1/GIP-RA [25] . GLP1-RAs also significantly affected the presence and activity of immune cells. Labelling of a marker of phagocytosis, ionized calcium-binding adaptor molecule 1 (Iba-1), was significantly reduced after exenatide [26, 29, 32, 35] and linagliptin administrations [41] . ED-1, a marker of inflammatory macrophages, showed a strong trend towards reduction by exenatide [32] . Microglia/macrophages are highly dynamic cells that can shift from an M2 antiinflammatory phenotype to an M1 pro-inflammatory phenotype following ischaemia. Exenatide significantly increased the number of anti-inflammatory macrophages in the injured hemisphere compared to the non-injured hemisphere [24] . Neutrophil infiltration was reduced by exenatide [26] and sitagliptin [36] , as shown in the latter study by reduced labelling of myeloperoxidase (MPO). Exenatide [18] , liraglutide [27] and sitagliptin [36] all reduced expression of the proinflammatory gene, nuclear factor kappa-light-chain enhancer of activated B cells (NF-jB). GLP-1-based therapies also affected BBB permeability. PEx-4 administration significantly reduced aquaporin 4 (AQ-4) and glial fibrillary acidic protein (GFAP) expression, which are both involved in neuroinflammation, oedema formation and astrogliosis [18] . PEx-4 also attenuated BBB endothelial leakage by decreasing the expression of intercellular adhesion molecule 1 (ICAM-1) [18] . Both exenatide and liraglutide reduced ICAM-1 compared to controls [27] . Exenatide also reduced expression of the matrix metallopeptidase (MMP-9) [26] , an enzyme that plays a significant role in cerebral oedema after stroke by breaking down the extracellular matrix [44] . Both PEx-4 [18] and rhGLP-1 [30] increased expression of endothelial NOS (eNOS), which helps maintain vascular homeostasis. Others found that exenatide and liraglutide increased phosphorylated eNOS (p-eNOS), although p-eNOS was not affected by the experimental stroke itself [27] . Linagliptin [41] and exenatide [26] reduced vascular immunoglobulin G (IgG) extravasation, indicating reduced endothelial leakage in the late inflammatory response to ischaemia. Linagliptin also significantly increased claudin-5 [41] , a cerebral endothelial tight junction protein, suggesting altered BBB function.
Glutamate release, which is involved in cellular excitotoxicity, was reduced by 60% following sitagliptin treatment [36] . Long-term pre-ischaemic treatment with alogliptin significantly increased production of brain-derived neurotrophic factor (BDNF) [42] , which can reduce the neurotoxic release of glutamate and stabilize neuroprotective GABAergic synapses with prolonged exposure.
Oxidative stress and cerebral oedema. Liraglutide and exenatide decreased the production of reactive oxygen species (ROS) [27] . One such ROS, superoxide anion (O 2 À ), was decreased by PEx-4 [18] . NADPH oxidase (NOx), an enzyme involved in the generation of ROS, was normalized in sitagliptin-treated animals [36] . Both linagliptin [41] and PEx-4 [18] reduced gp91, a subunit of superoxide-generating NOx. Dihydroethidium (DHE), used as a marker of ROS, was decreased by both exenatide and liraglutide [27] . Each of the GLP-1RAs and DPP-4Is tested augmented glutathione (GSH) and superoxide dismutase (SOD) [16, 17, 27, 30, 36] , which inhibit ROS production. Specifically, sitagliptin increased GSH levels up to 10.8 times in diabetic rats relative to a placebo-control group [36] . Liraglutide suppressed derivatives of reactive oxygen metabolites (d-ROMS) [28] . Lipid peroxidation, measured either by the marker malondialdehyde (MDA) or by thiobarbituric acid reactive substances (TBARS), was reduced by sitagliptin [36] , exenatide [16, 26, 27] , rhGLP-1 [30] and liraglutide [17] . Exenatide reduced protein oxidation, as shown by dinitrophenol (DNP) [26] . Sato et al. [28] found that liraglutide up-regulated the vascular endothelial growth factor (VEGF), a factor involved in angiogenesis under hypoxic conditions. Furthermore, PEx-4, exenatide and liraglutide [18, 27] all significantly reduced cerebral oedema, whereas the DPP-4I, alogliptin, had no effect [42] .
Apoptosis, neuronal damage and neuronal regeneration. The terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay is used to identify DNA damage. The number of TUNEL-positive cells was significantly reduced in ischaemic lesions by exenatide [26, 29] , liraglutide [17, 27, 31] and modified GLP-1RAs [21, 25] . However, the number of TUNEL-positive cells was reduced only by PEx-4 and not exenatide [18] . Exenatide [27, 34] , liraglutide [17, 27] , pro-GLP-1 [22] and modified GLP-1RAs [21, 25] increased expression of the anti-apoptotic factor B-cell lymphoma 2 (bcl-2) and reduced the pro-apoptotic factor Bcl-2-associated X protein (bax). Caspase 3 activity, involved in apoptosis, was reduced by pro-GLP-1 [22] , exenatide [23, 27] and the DPP-4I, sitagliptin [36] . Liraglutide down-regulated caspases 8 and 9 [31] , while sitagliptin reduced cytochrome c [36] . Exenatide reduced expression of 8-Oxo-2 0 -deoxyguanosine (8-OHdG), a marker of DNA damage [29] . Both exenatide and liraglutide attenuated expression of poly ADP-ribose polymerase (PARP) [45] , an enzyme that inhibits DNA repair [27, 31] . PEx-4 reduced bax/bcl-2 ratios, caspase 3 and PARP expression more effectively than exenatide [18] , and reduced gene expression of the CCAAT enhancer-binding protein homologous protein (CHOP), a marker of endoplasmic stress and apoptosis [18] . RhGLP-1 decreased expression of different markers of cerebral damage including S100 calcium-binding protein B (s100B), neuron-specific enolase (NSE) and myelin basic protein (MBP) [19] . Exenatide reduced Fluoro-Jade B-staining, which marks apoptotic cells [34] . Neuronal survival was significantly enhanced mainly by GLP-1RAs and to a lesser extent by DPP4Is [24, 30, 32, 34, 40] . However, in one study, only chronic (4 weeks pre-until 3 weeks post-ischaemia) [38] but not acute administration of linagliptin significantly affected neuron survival. Both GLP-1RA and linagliptin significantly reduced neuronal damage, as shown by Nissl staining [23, 41] .
In terms of neuronal regeneration, exenatide induced cell proliferation in the subventricular zone and neuroblast formation by 2 weeks after stroke, but no stroke-induced neurogenesis was reported [32] . Linagliptin enhanced neural stem cell proliferation but did not affect neuroblast production, neurogenesis or gliogenesis in mice with diabetes [39] .
Infarct volume and timing of administrations.
Sixteen studies evaluated the effects of GLP-1RAs on infarct volume and revealed a dose-dependent effect. In most studies, GLP-1RAs significantly reduced infarct volume when administered pre-ischaemia [16, 17, [19] [20] [21] [22] [23] , post-ischaemia [24, 25, 26, [28] [29] [30] [31] or both [32, 33] . Two studies more Fig. 2 . Proposed molecular mechanisms of GLPÀ1-based therapies in ischaemic stroke. Inflammation: ILÀ1b: InterleukinÀ1 beta, MCPÀ1: monocyte chemoattractant proteinÀ1, ILÀ10: interleukinÀ10, ILÀ6: interleukinÀ6, TNF-a: tumor necrosis factor alpha, iNOS:inducible nitric oxide synthases, NF-jB: nuclear factor kappa-light-chain enhancer of activated B cells, M2: anti-inflammatory macrophages, marked by CD206, arginase1 and YM1/2, HIFÀ1-a: hypoxia-inducible factor 1-alpha. Endothelial leakage: claudinÀ5: tight junction protein, ICAMÀ1: intercellular adhesion molecule 1, eNOS:endothelial nitric oxide synthases, AQÀ4: aquaporinÀ4, IgG: immunoglobulin G, MMPÀ9: matrix metallopeptidase 9. Excitotoxicity: BDNF: brain-derived neurotrophic factor, glutamate oxidative stress: GSH: glutathione, GSSG: glutathione disulfide, SOD: superoxide dismutase, O2-: superoxide radical, O2: oxygen; ROS: reactive oxygen species; NOx: nicotinamide adenine dinucleotide phosphate oxidase, H2O2: hydrogen peroxide, H2O: dihydrogen monoxide, VEGF: vascular endothelial growth factor, GFAP: glial fibrillary acidic protein, Apoptosis: PARP: poly ADP-ribose polymerase, BclÀ2: B-cell lymphoma 2, Bax: BclÀ2-associated X protein, Caspases: includes caspases 3, 8 and 9. Pathway proteins: cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, CREB: CAMP response element-binding protein, PI3K: phosphoinositide 3-kinase, Akt: protein kinase B. Markers not illustrated are EDÀ1: clone of antibody against cellular marker, CD68, MPO: myeloperoxidase, IbaÀ1: ionized calcium binding adaptor molecule 1, DHE: dihydroethidium, TBARS: thiobarbituric acid-reactive substances, MDA: malondialdehyde, DNP: dinitrophenol, CHOP: CCAAT/-enhancer-binding protein homologous protein, S100B: S100 calcium-binding protein B (s100B), NSE: neuron-specific enolase, MBP: myelin basic protein, TUNEL: terminal deoxynucleotidyl transferase dUTP nick end labeling, 8-OHdG: 8-OxoÀ2 0 -deoxyguanosine, ↑: enhancement, ↓: reduction, (↓): trend towards reduction, →: no significant change, paintbrush 2.1.2 and drawing toolkits from Motifolio Inc., were used to create artwork.
extensively investigated the timing of GLP-1RA administrations post-ischaemia. High doses of exenatide delivered 1.5 and 3 hr post-ischaemia were neuroprotective, but the effect was lost when the drug was administered at later time-points [24] . Correspondingly, others found that administrations of exenatide immediately after reperfusion conferred the greatest reduction in infarct volume relative to later administrations [29] . In contrast, the effects of DPP-4Is were more varied. One study showed a significant reduction in infarct volume when alogliptin was administered three weeks pre-ischaemia [42] , but only when administered at a moderate dose. Two other studies reported only small effects when linagliptin was administered long-term pre-ischaemia [38, 40] , more so in normal than diabetic mice. Finally, linagliptin and alogliptin did not affect infarct volume when administered only in the acute phase immediately after occlusion [38, 42] .
Functional outcome and cerebral blood flow. Nineteen studies reported effects of GLP-1RAs or DPP-4Is on functional outcome [16-23, 25-31, 33, 35, 41, 42] . Most GLP-1RA studies reported improved functional outcome, while only one of the two studies using DPP-4Is showed such an effect. In the first DPP-4I study, Ma et al. [41] found that linagliptin significantly ameliorated ischaemia-induced cognitive impairment in diabetic mice. However, the other DPP-4I study saw no effect of alogliptin, administered 3 weeks daily prior to stroke, on neurological deficits 7 days post-ischaemia [42] .
Studies reported conflicting results on the cerebrovascular effects of GLP-1RAs. Treatment with PEx-4 increased CBF [18] , thus suggesting that GLP-1RAs ameliorate vascular function in ischaemia. In contrast, three studies found that GLP1RAs did not affect CBF [20, 26, 28] . Similar variability was observed in the effects of DPP-4I administration on CBF when delivered post-ischaemia. Specifically, one study reported a significant improvement in CBF [41] and one did not [42] .
Quality of studies.
We used the ARRIVE guidelines to assess study quality, which are comprised of 20 items and have a maximum possible score of 38 [15] (details are given in table S1). All studies scored between 19 and 25 items, and the median score was 22 (interquartile range: 20-23). Generally, the type, source, total number and husbandry conditions of animals used were all well described, although the housing facility and welfarerelated assessments were not. The statistical methods were well reported, but methods to reduce bias, such as randomization, were poorly described. Sixteen of 27 (59%) studies used blinding during either procedures or data analysis. Details about the experimental procedure and facility during the procedure were well reported, but the rationale for choice of animal model, drug dose or administration route, and the time of day for experimental procedures were not. Also, the relevance to human biology, sample exclusion from analysis and sample size calculations were all poorly described. Only 4% of the studies stated if adverse events had been reported, and none of the studies described efforts made to reduce adverse events in animals.
Discussion
GLP-1-based therapies including GLP-1RAs and DPP-4Is
have been suggested to treat cardiovascular and cerebrovascular disorders, but so far large clinical trials have reported efficacy for only GLP-1RAs.
Based on evidence from animal stroke studies, we reported in this MiniReview that both GLP-1RAs and DPP-4Is affect several stroke-related signalling pathways in the ischaemic cascade including inflammatory, oxidative and apoptotic signalling. However, compared to GLP-1RAs, DPP-4Is had only a minor effect on infarct volume.
Activation of the GLP-1R initiates several intracellular pathways including the cAMP/PKA/CREB and PI3K/Akt. Both pathways are involved in neuroprotection and critically regulate the pathways underlying neuronal damage following ischaemia [21, 23] . GLP-1Rs are widely expressed in the brain, predominantly on neurons but also on astrocytes and microglia [46] . There are some reports suggesting that GLP1Rs are expressed in the peripheral endothelium [47] , but this is under debate.
The modified GLP-1RAs, designed to stimulate the GLP-1R more potently, enhanced the neuroprotective effects more than the clinically used GLP-1RAs. The GLP-1R agonist, DMB, has a higher receptor affinity than other GLP-1RAs and was more effective in combination with exenatide than each drug administered alone [21] . PEx-4 has a longer half-life than the clinically used exenatide and was significantly more neuroprotective [18] . Treatment with a dual-GLP-1/GIP receptor agonist conferred more neuroprotection than liraglutide alone [25] , suggesting that the incretin hormone, GIP, may also be involved in neuroprotection. The effects of GLP-1RAs generally appear more susceptible to GLP-1R suppression, as this diminished their neuroprotective effects significantly [21] [22] [23] . Intranasal administration of exenatide rapidly concentrated GLP-1RAs in the brain and showed a significantly greater reduction in infarct volume than intraperitoneal administration. This suggests that rapid activation of cerebral GLP-1Rs plays a role in neuroprotection [23] . Notwithstanding, the role of the cerebral GLP-1R is unknown. To increase the therapeutic potential of GLP-1RAs, future studies should investigate the effects of GLP-1RAs on the cerebral endothelium and the degree to which GLP-1RAs pass either an intact or disrupted BBB. The studies currently included may have applied nonspecific antisera to localize GLP-1R expression [48] , and some did not investigate GLP-1R expression to locate the target of their GLP-1RA treatment.
DPP-4Is were neuroprotective in mice lacking the GLP-1R [38] . This suggests that DPP-4Is are more likely to activate targets independent of the GLP-1R, indicating a non-specific mechanism of action that could explain the lack of cardiovascular effects seen in human studies. This supports that the GLP-1R is a key player in cardiovascular protection. In a previous study, R€ ohnert et al. [37] demonstrated that reduction in infarct volume was seen for non-selective DPP-Is, but not for the selective DPP-4I. They also suggested that targeting the inflammatory component of stroke with multiple peptidases is important for neuroprotection. In the studies reported in this MiniReview, DPP-4Is increased the concentration of GLP-1. However, nonspecific binding of DPP-4Is may have off-target effects that could counteract any potential cardiovascular benefits. Dosedependent responses were primarily reported for GLP-1RAs but not DPP-4Is; however, this relationship was not strictly linear. Higher drug doses increased the effects of GLP-1RA nonlinearly, suggesting that GLP-1R-independent mechanisms might enhance the protective effects seen at higher doses [32] .
Timing of drug administration significantly influenced the effect of drugs on infarct volume, with differential effects on GLP-1RAs and DPP-4Is. The use of GLP-1RAs immediately post-stroke seems promising with a potential therapeutic window of up to three hours in mice, which approximates to 36 hr in human beings [42] . This suggests that GLP-1RAs may have a longer therapeutic window than the 4.5 hr allowed for tPA treatment, and highlights the therapeutic potential for GLP-1RAs in acute stroke. DPP-4Is administered in the acute phase had less effect on infarct volume. The differential effects of timing on GLP-1RAs and DPP-4Is may be explained by their different mechanisms of action.
In newly published retrospective studies, GLP-1RAs reduce the risk of cardiovascular disease (CVD) events in diabetic patients. The LEADER trial concluded that among diabetic patients with an increased risk of CVD events, liraglutide treatment significantly reduced CVD-related deaths compared to placebo [5] . In the SUSTAIN-6 trial [4] , semaglutide reduced the risk of both fatal and non-fatal CVD events in patients with type 2 diabetes. However, for both GLP-1RAs and DPP-4Is, clinical trials were designed to investigate the effect on the frequency of cardiovascular events in diabetic patients, but not stroke patients specifically. The effects on treatment regimen/secondary prevention in ischaemic stroke patients have not been fully investigated. Studies investigating the effects of GLP-1RAs specifically on stroke patients are highly warranted. The difference in pharmacological properties of the GLP-1RAs should be considered when choosing GLP1RAs for acute versus chronic stroke treatment. For example, a short-acting GLP-1RA that can rapidly pass the BBB may be preferable in acute stroke settings.
To fully assess the effects of DPP-4Is in stroke, their mechanisms of actions must be critically considered. Results from animal studies using DPP-4Is to treat cardio-and cerebrovascular diseases have failed to translate to clinical trials including diabetic patients. This failure could be explained by their unspecific mechanisms of action and low penetration of the BBB. Possible mechanisms of action for DPP-4Is were included in this MiniReview to highlight potential treatment targets. Clinical trials examining the effects of DPP-4Is on the ischaemic brain may be warranted if the proposed mechanism for cardiovascular protection is established and translation to human beings can be demonstrated.
When investigating stroke mechanisms in animals, a basic requirement for the stroke models is the induction of a significant but preferably temporary artery occlusion in animals. Ideally, these studies would use animals with similar risk factors as human beings including old age, hypertension, obesity and diabetes. Furthermore, duration of the ischaemic period strongly affects outcome. The studies reviewed here varied largely in occlusion time, with periods ranging from 5 min. to permanent occlusion. Only three of the 27 studies measured the regional CBF during and after occlusion induction [24, 26, 29] to ensure a sufficient occlusion. Interestingly, four studies found that the neuroprotective effects of both GLP-1RAs and DPP-4Is were stronger in the cortex than the striatum [24, 28, 32, 37] . This may be explained by better collateral perfusion in the cortex, or that the cortex contains the ischaemic penumbra, where neuroprotective interventions are more effective.
Blood glucose and insulin levels may affect the pathophysiology and outcome of stroke [49, 50] . However, it seems unlikely that the positive effects seen in the reviewed animal studies result solely from alterations in glucose and insulin levels. Indeed, the neuroprotective effects of these drugs were seen in animals both with and without diabetes [17, 24, 40] , and no significant changes in glucose and insulin levels were found in animals without diabetes [21-23, 29, 42] . However, one study reported that liraglutide decreased stress-induced hyperglycaemia [31] . Insulin, which also reduces blood glucose levels, did not have the same neuroprotective effects as GLP-1RAs in diabetic animals [17, 19] .
Some limitations apply to this review, as we chose not to include in vitro studies and mainly focused on possible mechanisms of action in the stroke pathophysiology of animals. The review included studies of bilateral stroke models, which do not mimic naturally occurring strokes. We also chose not to include studies of induced cerebral haemorrhage or haemorrhagic transformation, as these events have different underlying pathophysiology than ischaemic stroke. Finally, we did not estimate the publication bias favouring positive outcome.
In conclusion, published animal studies suggest that GLP-1-based therapies, particularly GLP-1RAs, are neuroprotective in both diabetic and non-diabetic animals. GLP-1-based therapies significantly affected inflammation, oxidative stress and apoptosis processes that occur secondary to stroke. However, compared to GLP-1RAs, DPP-4Is had only a minor effect on infarct volume. GLP-1-RAs improved functional outcome, but inconclusive effects on CBF were reported. Stimulation of the GLP-1R was important for the neuroprotective effects, but some GLP-1R-independent effects were suggested, especially by DPP-4Is. Both GLP-1RAs and DPP-4Is were effective using long-term pre-ischaemia administrations, although only the GLP-1RA results seem to translate to human beings. Administrations of GLP-1RAs (and perhaps DPP-4Is) prior to stroke, and GLP-1RAs immediately after, are the most promising to pursue. However, administration immediately after stroke is the most clinically relevant. Limitations in the number of animal comorbidities, such as hypertension, are essential for data interpretation. Clinical trials are required to address the effects of GLP-1-RAs in both acute and prophylactic stroke settings. Further investigations will improve our knowledge of optimal GLP-1RA administration conditions in stroke settings.
